Repros Therapeutics (NASDAQ: RPRX) and Sorrento Tech (NASDAQ:ROKA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Institutional and Insider Ownership

How to Become a New Pot Stock Millionaire

13.6% of Repros Therapeutics shares are owned by institutional investors. Comparatively, 48.1% of Sorrento Tech shares are owned by institutional investors. 2.5% of Repros Therapeutics shares are owned by company insiders. Comparatively, 29.2% of Sorrento Tech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Repros Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Sorrento Tech has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Repros Therapeutics and Sorrento Tech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repros Therapeutics 0 1 0 0 2.00
Sorrento Tech 0 0 0 0 N/A

Repros Therapeutics currently has a consensus target price of $0.39, indicating a potential downside of 41.79%. Given Repros Therapeutics’ higher probable upside, equities analysts clearly believe Repros Therapeutics is more favorable than Sorrento Tech.

Earnings and Valuation

This table compares Repros Therapeutics and Sorrento Tech’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Repros Therapeutics $50,000.00 530.10 -$17.27 million ($0.50) -1.34
Sorrento Tech $7.24 million 0.45 -$30.78 million ($8.79) -0.07

Repros Therapeutics has higher earnings, but lower revenue than Sorrento Tech. Repros Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Tech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Repros Therapeutics and Sorrento Tech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repros Therapeutics N/A N/A -134.23%
Sorrento Tech 3.30% 2.05% 1.00%

Summary

Sorrento Tech beats Repros Therapeutics on 8 of the 12 factors compared between the two stocks.

About Repros Therapeutics

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

About Sorrento Tech

Sorrento Tech, Inc., formerly Roka Bioscience, Inc., is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.